ReviewAsian journal of pharmaceutical sciences2024
Stem cell-based ischemic stroke therapy: Novel modifications and clinical challenges.
Review in Asian journal of pharmaceutical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Therapeutic efficacy of genetically engineered neural stem cells in cerebral ischemia: a systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- Targeting Microglial HDAC5 Suppresses NLRP3 Inflammation via NF-κB Deacetylation to Alleviate Ischemic Brain Injury.CNS neuroscience & therapeutics · 2026Article
- PET molecular imaging of in vivo brain metabolism, synaptic density and glial reactivity changes after neural stem cell transplantation on a rat model of ischemic stroke.European journal of nuclear medicine and molecular imaging · 2026Article
- Advances and applications of brain organoids in central nervous system disorders: Bridging the gap from laboratory to clinic.Neural regeneration research · 2026Article
- Neural stem cell-derived exosomal PA2G4 induces ANXA2 degradation to promote mitophagy and alleviate neuronal oxidative stress in cerebral ischemia/reperfusion.Apoptosis : an international journal on programmed cell death · 2026Article
- Transplantation of Skin-Derived Precursor Schwann Cells Ameliorates Secondary Brain Injury after ICH in Mice by Activating the PI3K/AKT/FOXO3a Signaling Pathway.Translational stroke research · 2026Article
- Molecular imaging of stem cell therapies in ischemic stroke.European journal of nuclear medicine and molecular imaging · 2025Review
- Review
- Low-Intensity pulsed ultrasound enhances paracrine secretion of IGF and VEGF by bmscs, promoting osteogenesis and angiogenesis.BMC musculoskeletal disorders · 2025Article
- Stem Cell Therapy Approaches for Ischemia: Assessing Current Innovations and Future Directions.International journal of molecular sciences · 2025Review
- Effects of stem cell therapy on preclinical stroke.Open veterinary journal · 2025Review
- Focusing on Microenvironmental Disturbance to Potentiate Reparative Ability of Neural Stem Cell After Stroke.Research (Washington, D.C.) · 2025Review
- From Bench to Bedside: The Evolving Landscape of Stem Cell Therapies for Stroke Rehabilitation.Stem cells international · 2025Review
- Extracellular vesicles for delivering therapeutic agents in ischemia/reperfusion injury.Asian journal of pharmaceutical sciences · 2024Article
- Advanced Nano-Drug Delivery Systems in the Treatment of Ischemic Stroke.Molecules (Basel, Switzerland) · 2024Review
- Article
- Bioactive Materials Facilitate the Restoration of Neurological Function Post Cerebral Ischemic Stroke.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (IS) causes severe disability and high mortality worldwide. Stem cell (SC) therapy exhibits unique therapeutic potential for IS that differs from current treatments. SC's cell homing, differentiation and paracrine abilities give hope for neuroprotection. Recent studies on SC modification have enhanced therapeutic effects for IS, including gene transfection, nanoparticle modification, biomaterial modification and pretreatment. These methods improve survival rate, homing, neural differentiation, and paracrine abilities in ischemic areas. However, many problems must be resolved before SC therapy can be clinically applied. These issues include production quality and quantity, stability during transportation and storage, as well as usage regulations. Herein, we reviewed the brief pathogenesis of IS, the "multi-mechanism" advantages of SCs for treating IS, various SC modification methods, and SC therapy challenges. We aim to uncover the potential and overcome the challenges of using SCs for treating IS and convey innovative ideas for modifying SCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.